Recurrence prediction using circulating tumor DNA in patients with early-stage non-small cell lung cancer after treatment with curative intent: A retrospective validation study
ctDNA detection predicted recurrence in independent retrospective cohorts with notable reproducibility, including near-identical detection rates and predictive values, confirming its ability to differentiate patients at high- versus low risk of recurrence. Our results support the potential of tissue-informed ctDNA analysis as a decision-support tool for adjuvant therapy in NSCLC.
Authors
- Anna Paterson (ORCID: https://orcid.org/0000-0002-1494-0875)
- Koen J. Hartemink (ORCID: https://orcid.org/0000-0003-4282-1096)
- Milou Schuurbiers (ORCID: https://orcid.org/0000-0002-0843-8897)
- Christopher G. Smith (ORCID: https://orcid.org/0000-0001-7357-2737)
- Kim Monkhorst (ORCID: https://orcid.org/0000-0002-8690-3811)
- Nitzan Rosenfeld (ORCID: https://orcid.org/0000-0002-2825-4788)
- Michel M. van den Heuvel (ORCID: https://orcid.org/0000-0002-6372-2153)
- Daan van den Broek (ORCID: https://orcid.org/0000-0002-0514-9811)
- Davina Gale (ORCID: https://orcid.org/0000-0002-4521-8199)
- Robert C. Rintoul (ORCID: https://orcid.org/0000-0003-3875-3780)
- Bas L R Mandos
Institutions
- Radboud University Nijmegen (NL)
- Queen Mary University of London (GB)
- University of Cambridge (GB)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- Radboud University Medical Center (NL)
- The Netherlands Cancer Institute (NL)
- Cancer Research UK Cambridge Center (GB)
- Bridge University (SS)
- Papworth Hospital NHS Foundation Trust (GB)
- Oncode Institute (NL)
- NeoGenomics (United States) (US)
Publication Details
- Journal
- PLoS Medicine
- Published
- 2025-04-15
- DOI
- https://doi.org/10.1371/journal.pmed.1004574
- Citations
- 7
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 6.55
Funders
- AstraZeneca
- Novartis
- Roche Nederland
- Cancer Research UK
- Radboud Universiteit
- Radboud Universitair Medisch Centrum
- Pfizer Pharmaceuticals
- NIHR Cambridge Biomedical Research Centre
- Cancer Research UK Cambridge Institute, University of Cambridge